文献速递消化道肿瘤与早癌肝病

肝细胞癌特殊人群的系统治疗

Systemic treatment of HCC in special populations.
PubMed 文献 · J Hepatol · 2020-11-26

本综述总结了肝细胞癌系统治疗在合并HIV、自身免疫病、心血管病、糖尿病、失代偿期肝硬化、显著出血史、血管侵犯或门静脉血栓、高龄、血液透析及实体器官移植后等特殊人群中的应用现状。文章指出,由于大型III期试验排除了合并症患者,这些人群缺乏高质量证据,并强调未来试验应专门纳入合并症患者。

要点

  • 特殊人群(如合并症、器官移植后)缺乏系统治疗的高质量证据。
  • 现有大型III期试验排除了合并症患者,导致证据外推受限。
  • 未来试验应专门纳入合并症患者以改善安全性和疗效。

核心结论

  • 肝细胞癌特殊人群的系统治疗证据有限,未来试验需专门纳入合并症患者。

研究设计与样本

  • 综述,总结已批准药物在肝细胞癌特殊人群中的应用。

主要发现

  • 大型III期试验聚焦高度选择患者,排除了潜在混淆的合并症,导致特殊人群高质量证据缺失。

临床怎么用

  • 临床决策需参考现有有限证据,关注特殊人群的治疗安全性和疗效。

局限性

  • 缺乏针对特殊人群的高质量证据,现有数据多来自排除合并症患者的试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirrhosis (Child-Pugh B and C), a significant bleeding history, vascular invasion or portal vein thrombosis, as well as the elderly, those on haemodialysis, and those after solid organ transplantation. The article highlights relevant knowledge gaps and current clinical challenges. To improve the safety and efficacy of HCC treatment in these subgroups, future trials should be designed to specifically include patients with comorbidities.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Rimassa L, Personeni N, Czauderna C, et al. Systemic treatment of HCC in special populations. J Hepatol. 2020. PMID: 33248171. doi:10.1016/j.jhep.2020.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。